Product Overview
Virionics is focused on the development of vaccines and immunotherapies against
diseases where no effective vaccines or immunotherapies exist.
Clinical and/or research data from MediGene AG, National Institutes of Health
(NIH) and our other collaborators indicate that our licensed virus-like particle
(VLP) technology is extremely effective in preventing and treating a broad range
of chronic diseases and provides effective protection against a wide variety
of acute life-threatening diseases. VLPs can be used to prevent disease, treat
existing disease, and to generate human immune globulins that can be used to
treat disease.
The product pipeline table below lists our VLP programs and their stage of
clinical development:
Product Pipeline
PapViRx™
HPV related CIN II/III Therapy |
| |
|
|
|
|
 |
|
HepCVax™
Chronic HCV Prevention |
| |
|
|
|
|
|
|
HepCiRx™
Acute HCV Therapy |
| |
|
|
|
|
|
|
CIgImmune™
for Liver Transplantation |
| |
|
|
|
|
|
|
RetroVax™
VLP + AVAXIN™-CCR5 |
| |
|
|
|
|
|
|
|
